Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease.

Inflammatory bowel disease (IBD) is an immunoinflammatory illness of the gut initiated by an immune response to bacteria in the microflora. The resulting immunopathogenesis leads to lesions in epithelial lining of the colon through which bacteria may infiltrate the tissue causing recurring bouts of diarrhea, rectal bleeding, and malnutrition. In healthy individuals such immunopathogenesis is avoided by the presence of regulatory cells that inhibit the inflammatory pathway. Highly relevant to the search for treatment strategies is the identification of components of the inflammatory pathway that allow regulatory mechanisms to be overridden and immunopathogenesis to proceed. In vitro techniques have identified cellular interactions involved in inflammation-regulation crosstalk. However, tracing immunological mechanisms discovered at the cellular level confidently back to an in vivo context of multiple, simultaneous interactions has met limited success. To explore the impact of specific interactions, we have constructed a system of 29 ordinary differential equations representing different phenotypes of T-cells, macrophages, dendritic cells, and epithelial cells as they move and interact with bacteria in the lumen, lamina propria, and lymphoid tissue of the colon. Simulations revealed the positive inflammatory feedback loop formed by inflammatory M1 macrophage activation of T-cells as a driving force underlying the immunopathology of IBD. Furthermore, strategies that remove M1 from the site of infection, by either (i) increasing its potential to switch to a regulatory M2 phenotype or (ii) increasing the rate of reversion (for M1 and M2 alike) to a resting state, cease immunopathogenesis even as bacteria are eliminated by other inflammatory cells. Based on these results, we identify macrophages and their mechanisms of plasticity as key targets for mucosal inflammation intervention strategies. In addition, we propose that the primary mechanism behind the association of PPARgamma mutation with IBD is its ability to mediate the M1 to M2 switch.

[1]  David Harel,et al.  The Lymph Node B Cell Immune Response: Dynamic Analysis In-Silico , 2008, Proceedings of the IEEE.

[2]  S. Pettersson,et al.  Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA , 2004, Nature Immunology.

[3]  Johan Auwerx,et al.  Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis , 2003 .

[4]  Ian B Hogue,et al.  The dual role of dendritic cells in the immune response to human immunodeficiency virus type 1 infection. , 2008, The Journal of general virology.

[5]  M. Jensen-Waern,et al.  Immunological alterations during the clinical and recovery phases of experimental swine dysentery. , 2006, Journal of medical microbiology.

[6]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[7]  S. Gordon,et al.  Inflammation: Glucocorticoids turn the monocyte switch , 2007, Immunology and cell biology.

[8]  Leo Lefrançois,et al.  Initial T cell frequency dictates memory CD8+ T cell lineage commitment , 2005, Nature Immunology.

[9]  Vidya Subramanian,et al.  Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. , 2008, Cell metabolism.

[10]  F. Sallusto,et al.  Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. , 2003, Blood.

[11]  A. Iwasaki.  Mucosal dendritic cells. , 2007, Annual review of immunology.

[12]  N. D. Di Paolo,et al.  Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells , 2007, Nature.

[13]  Erin Nevius,et al.  Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Immunoregulation: Enhancement of Regulatory T Cells through PPARγ-Dependent and -Independent Mechanisms , 2007, The Journal of Immunology.

[14]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[15]  Judy H. Cho,et al.  The genetics and immunopathogenesis of inflammatory bowel disease , 2008, Nature Reviews Immunology.

[16]  A. Haase,et al.  Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. , 1999, Annual review of immunology.

[17]  Manfred Dietel,et al.  Mucosal flora in inflammatory bowel disease. , 2002, Gastroenterology.

[18]  Marc K Jenkins,et al.  Visualizing the first 50 hr of the primary immune response to a soluble antigen. , 2004, Immunity.

[19]  C Reder,et al.  Metabolic control theory: a structural approach. , 1988, Journal of theoretical biology.

[20]  B. Spiegelman.  PPARγ in Monocytes: Less Pain, Any Gain? , 1998, Cell.

[21]  F. Powrie,et al.  Characterization of Foxp3+CD4+CD25+ and IL-10-Secreting CD4+CD25+ T Cells during Cure of Colitis1 , 2006, The Journal of Immunology.

[22]  Avner Friedman,et al.  Modeling the immune rheostat of macrophages in the lung in response to infection , 2009, Proceedings of the National Academy of Sciences.

[23]  Alan S. Perelson,et al.  Agent-based modeling of host–pathogen systems: The successes and challenges , 2008, Information Sciences.

[24]  Fiona Powrie,et al.  An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation , 1999, The Journal of experimental medicine.

[25]  James L Riley,et al.  Human T regulatory cell therapy: take a billion or so and call me in the morning. , 2009, Immunity.

[26]  Frank Brombacher,et al.  Macrophage-specific PPARγ controls alternative activation and improves insulin resistance , 2007, Nature.

[27]  C. Moskaluk,et al.  Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. , 2005, Gastroenterology.

[28]  S. Grundy,et al.  Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association , 2003, Diabetes care.

[29]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[30]  D. Greaves,et al.  Autocrine Deactivation of Macrophages in Transgenic Mice Constitutively Overexpressing IL-10 Under Control of the Human CD68 Promoter1 , 2002, The Journal of Immunology.

[31]  I. Braverman.  Skin signs of gastrointestinal disease. , 2003, Gastroenterology.

[32]  J. Hampe,et al.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease , 2004, Gut.

[33]  Denise Kirschner,et al.  A Model to Predict Cell-Mediated Immune Regulatory Mechanisms During Human Infection with Mycobacterium tuberculosis1 , 2001, The Journal of Immunology.

[34]  A. Cunningham,et al.  Dendritic Cells and Monocyte/Macrophages That Create the IL-6/APRIL-Rich Lymph Node Microenvironments Where Plasmablasts Mature1 , 2009, The Journal of Immunology.

[35]  Maurice Clerc,et al.  The particle swarm - explosion, stability, and convergence in a multidimensional complex space , 2002, IEEE Trans. Evol. Comput..

[36]  S. Nakagawa,et al.  A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. , 2003, Gastroenterology.

[37]  Raquel Hontecillas,et al.  Peroxisome Proliferator-Activated Receptor γ Is Required for Regulatory CD4+ T Cell-Mediated Protection against Colitis , 2007, The Journal of Immunology.

[38]  M. Fink,et al.  IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[39]  W. Stenson.  Interleukin-4 hyporesponsiveness in inflammatory bowel disease: immune defect or physiological response? , 1995, Gastroenterology.

[40]  M. Engelgau,et al.  The continuing increase of diabetes in the US. , 2001, Diabetes care.

[41]  G. Barba,et al.  Pancréatite récurrente révélant une maladie de Crohn , 2002 .

[42]  R. Coffman,et al.  Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. , 1993, International immunology.

[43]  J. Bassaganya-Riera,et al.  CD4+ T‐cell responses and distribution at the colonic mucosa during Brachyspira hyodysenteriae‐induced colitis in pigs , 2005, Immunology.

[44]  Ulrich H. von Andrian,et al.  Homing and cellular traffic in lymph nodes , 2003, Nature Reviews Immunology.

[45]  Antonio Lanzavecchia,et al.  Regulation of T Cell Immunity by Dendritic Cells , 2001, Cell.

[46]  D. Artis.  Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut , 2008, Nature Reviews Immunology.

[47]  S. Sakaguchi,et al.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation , 1996, The Journal of experimental medicine.

[48]  Mudita Singhal,et al.  COPASI - a COmplex PAthway SImulator , 2006, Bioinform..

[49]  S. Gordon,et al.  Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.

[50]  Anna Chodos,et al.  Antigen-dependent Proliferation of CD4+ CD25+ Regulatory T Cells In Vivo , 2003, The Journal of experimental medicine.

[51]  Shimon Sakaguchi,et al.  Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation , 2008, Proceedings of the National Academy of Sciences.

[52]  M. Blaser,et al.  Dynamics of Helicobacter pylori colonization in relation to the host response. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Tough,et al.  Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. , 2002, Blood.

[54]  R. Blumberg,et al.  The immunology of mucosal models of inflammation. , 2002, Annual review of immunology.

[55]  J. Gustafsson,et al.  Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. , 1996, Biochemical and biophysical research communications.

[56]  D. Straus,et al.  the Peroxisome Proliferator‐Activated Receptor &ggr; Ligand Rosiglitazone Delays the Onset of Inflammatory Bowel Disease in Mice With Interleukin 10 Deficiency , 2005, Inflammatory bowel diseases.

[57]  J. Bassaganya-Riera,et al.  Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease , 2004 .

[58]  C. Janeway.  Immunobiology: The Immune System in Health and Disease , 1996 .

[59]  Paul Rutgeerts,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY , 2009 .